GLASGOW, Scotland, Jan. 27, 2021 /PRNewswire/ -- MGB Biopharma, a biopharmaceutical company developing MGB-BP-3, a novel antibacterial, for the treatment of Clostridioides difficile (CDI), today announces the successful completion of its End-of-Phase 2 (EOP2) meeting with the US Food and Drug Administration (FDA), an important milestone for the company and its lead product.
GLASGOW, Scotland, May 19, 2020 /PRNewswire/ -- MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives, today announces that its Phase II clinical study has met its endpoints of safety, efficacy, and dose selection. The study confirms that MGB-BP-3, an antibacterial, has the potential to become the new gold standard, first-line treatment for CDI.
GLASGOW, Scotland, May 19, 2020 /PRNewswire/ -- MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives, today announces that its Phase II clinical study has met its endpoints of safety, efficacy, and dose selection. The study confirms that MGB-BP-3, an antibacterial, has the potential to become the new gold standard, first-line treatment for CDI.
MGB Biopharma has announced an update on progress in its Phase IIa clinical study assessing the safety, tolerability and efficacy of incremental doses of MGB-BP-3 in patients with clostridium difficile-associated diarrhoea (CDAD).
MGB Biopharma has raised money to finish a phase 2a trial of its lead antibiotic MGB-BP-3 in people with Clostridium difficile-associated diarrhea. The small financing positions MGB to generate clinical data and prepare for next steps.
Catalent announced the initiation of Phase II clinical trials of MGB Biopharma’s lead candidate, MGB-BP-3, an orally-dosed drug targeting the eradication of Clostridium difficile-associated diarrhea (CDAD). The two companies have collaborated to accelerate the drug formulation, manufacture and distribution of the drug.
MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, announces that the Food and Drug Administration (FDA) and Health Canada have cleared Investigational New Drug applications (IND/CTA) for its lead candidate MGB-BP-3. The Company intends to commence its dose-range finding Phase IIa clinical trial, in the US and Canada, on MGB-BP-3 for the treatment of Clostridium difficile-associated diarrhoea (CDAD) in Q1 2019.